Skip to Content

Weiss Asset Management LP acquires 16,050 Amgen Inc. shares (NASDAQ:AMGN)

Weiss Asset Management LP acquires 16,050 Amgen Inc. shares (NASDAQ:AMGN)

Weiss Asset Management LP is reported to have acquired a new stake in Amgen Inc. (NASDAQ: AMGN) during the third quarter, as stated in the company’s most recent filing with the Securities and Exchange Commission (SEC). The fund spent approximately $3,618,000 to purchase 16,050 shares of stock in the medical research organization, bringing the total amount spent by the fund to approximately $3,618,000.

Hedge funds and other types of institutional investors have been increasing the percentage of their holdings invested in the company over the past few months. During the second quarter, Private Advisor Group LLC completed a 16.7% increase in Amgen stock held in its portfolio. Since the beginning of the most recent quarter, Private Advisor Group LLC has increased its stake in the company by 9,239, bringing the total number of shares it owns in the medical research firm to 64,413. These shares are currently worth a total of $15,672,000 as of right now. Culbertson, AN & Co., Inc. increased the amount of Amgen stock owned by 19.8 percentage points during the third quarter. Following the acquisition of 240 additional shares during the most recent quarter, Culbertson A. N. & Co., Inc. now owns 1,450 shares in the medical research company, with a value of $326,000. This brings the total number of shares directly owned by the company to 1,450. During the second quarter, Asset Dedication LLC achieved an 11.8% increase in the proportion of Amgen stock it owned. Asset Dedication LLC now has 11,931 shares in its possession after purchasing an additional 1,259 shares during the most recent quarter. This results in a market capitalization of $2,875,000 for the company. Quilter increased the proportion of Amgen shares owned by 3.0% over the first quarter. Quilter Plc now has 5,158 shares of the stock held by the medical research company after acquiring an additional 150 shares during the most recent fiscal quarter. This brings the total number of shares held by Quilter Plc to 5,158. The total worth of these shares comes to 1,248,000 dollars. And finally, during the second quarter, Mather Group LLC increased its holdings in Amgen by 2.3% by purchasing additional shares. As a result, Mather Group LLC now owns 4,097 shares in the medical research firm, with a value of $997,000. Since the close of the most recent financial quarter, this represents an increase of 91 shares. Currently, 75.53% of the company’s shares are owned by hedge funds and other institutional investors.

In recent years, AMGN has been able to pique the interest of a variety of research companies. The rating on the shares of Amgen that Barclays has assigned has been changed from “equal weight” to “underweight,” and the new price objective for the stock has been established at $234.00. A report was made available to the general public on Monday, October 31st, by research companies. The rating on the shares of Amgen that Barclays has assigned has been changed from “equal weight” to “underweight,” and the new price objective for the stock has been established at $234.00. A report was made available to the general public on Monday, October 31st. In a report distributed on the 22nd of December, SVB Leerink rated the stock as “market perform” and increased their price target on Amgen shares from $256.00 to $282.00.

Additionally, they raised their price target on Amgen shares from $256.00 to $282.00. The “buy” rating that StockNews.com had previously assigned to Amgen’s shares was raised to a “strong-buy” recommendation in a report published on Friday, January 6th. Oppenheimer upgraded their rating on the stock to “outperform” from “market perform” in a report released on Tuesday, December 6th. Additionally, they increased their price objective on Amgen shares from $300.00 to $310.00. Finally, but certainly not least, in a report dated November 8th, Trust Financial increased its price objective on Amgen shares from $266.00 to $280.00 while maintaining its “hold” rating on the stock. There is one research analyst who assigned a strong buy rating to the stock; four research analysts assigned a buy rating to the stock, four research analysts assigned a hold rating to the stock, and four research analysts assigned a sell rating to the stock. According to a report by Bloomberg, the stock has been given an average rating of “Hold,” and the price objective has been established at $253.57.

Other recent developments concerning Amgen include that on November 8, Senior Vice President Nancy A. Grygiel sold 545 shares. The shares were sold for $159,979.30, equivalent to an average price per share of $293.54. The price per share was determined by dividing the total amount by the number of shares sold. Following the completion of the transaction, the senior vice president will have a total of 13,009 shares in the company. These shares have an approximate value of $3,818,661.86 at present. Access to the legal file that details the transaction’s disclosure can be gained through the Securities and Exchange Commission’s (SEC) website. This file can be found on the website. The company’s insiders own 0.46 percent of the total number of shares that are currently outstanding.

There were 31,751 NASDAQ: AMGN shares traded on Friday, a decrease of $0.43 compared to the average volume of 2,094,364 shares traded on the previous trading day. At the close of trading for the day, the stock price was $270.49. It has a price-to-earnings ratio of 21.73, a price-to-earnings-growth ratio of 1.95, and a beta value of 0.67. All of these measures are relative to the company’s current stock price. The company is currently valued at $144.33 billion on the market. This company’s moving average for the previous 200 days is $255.78, and the moving average for the previous 50 days is $276.21. The ratio of total liabilities to total equity is 10.17, the ratio of current assets to total assets is 1.68, and the ratio of quick assets to current assets is 1.35. During the previous year, the price of a share of Amgen Inc. fluctuated between $214.39 and $296.67, reaching a low of $214.39 and a high of $296.67.

Amgen (NASDAQ: AMGN) issued a press release announcing the publication of its most recent earnings report on November 3rd. The medical research company reported earnings per share for the quarter of $4.70, which was $0.27 higher than the estimate taken as the consensus among market experts. The revenue for the quarter was $6.65 billion, which was higher than the consensus estimate of $6.56 billion for the revenue that should have been generated during the quarter. Amgen’s net margin and return on equity were both exceptionally high, coming in at 24.96% and 287.23%, respectively. Compared to the same quarter of the previous year, the revenue for this quarter was down by 8.8 percentage points. In the same period as the previous year, the company reported earning $4.67 in profit for each share of common stock outstanding. According to the consensus among financial experts, Amgen Inc. is expected to generate earnings of 17.62 cents per share during the current fiscal year.

The particulars of a quarterly dividend were disclosed by the company not too long.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *